The RelA(p65) NF-κB (nuclear factor κB) subunit is typically thought of as being antiapoptotic and tumourpromoting. However, in our laboratory, we have discovered that RelA can inhibit, rather than induce, antiapoptotic gene expression when activated by certain chemotherapeutic drugs, UV light or through the action of the ARF tumour suppressor. These observations explain why RelA can sometimes facilitate rather than inhibit apoptosis and also exhibits tumour-suppressor characteristics in vivo. A better understanding of these processes and an ability to analyse RelA function in tumours could lead to improved cancer diagnosis, choice of therapy and, ultimately, development of new drugs.
high levels of inflammatory cytokines or hypoxic conditions, which activate NF-κB DNA binding [7] [8] [9] . Significantly, oncoproteins, such as Bcr-Abl and Ras, require NF-κB activity to induce cellular transformation [8] . In addition, many viral oncoproteins also induce NF-κB activity [10] . More rarely, rearrangements, amplifications and missense mutations have been reported for NF-κB subunits [11] , whereas loss of function mutations in IκB proteins, resulting in aberrantly active NF-κB, have been found in cases of Hodgkins lymphoma [11] . Alternatively, the loss of negative feedback mechanisms, which usually serve to limit the NF-κB response, can also result in its aberrant activity. An example of this is the CYLD tumour-suppressor gene and deubiquitinating enzyme. Loss of CYLD, which is associated with a predisposition to familial cylindromatosis (tumours of skin appendages), leads to aberrant NF-κB activation [12] [13] [14] .
RelA can promote tumourigenesis through its ability to induce the expression of antiapoptotic genes such as Bcl-X L , X-IAP and IEX-1 [15, 16] . Confirming the importance of this pathway, rela −/− mice die in utero as a result of TNFα (tumour necrosis factor α)-induced apoptosis of liver cells [4] . However, there are other aspects of NF-κB function that can promote tumour growth and survival. For example, the cyclin D1 and c-Myc promoters are targets of NF-κB [17, 18] . NF-κB also has the potential to regulate metastasis through its ability to induce the expression of cellular adhesion molecules and matrix metalloproteinases [7, 8, 19, 20] . NF-κB can also promote tumour growth by inducing genes such as cyclo-oxygenase 2 [7, 8] . Under these circumstances, NF-κB can be essentially thought of as functioning like an oncogene. Inhibition (or modulation) of NF-κB function would, therefore, target many tumour cell characteristics, and animal models have supported the probable beneficial effects of such treatments [7] [8] [9] . NF-κB can also inhibit the apoptosis induced by some common cancer chemotherapeutic drugs and ionizing radiation [8, 15] . Since these treatments also induce NF-κB DNA binding, this means that, even in those tumours that do not display intrinsically aberrant levels of NF-κB activity, its inhibition could provide a method of enhancing the effectiveness of cancer therapy.
NF-κB as a tumour suppressor
NF-κB (and RelA) DNA binding can be induced by a wide variety of stimuli [19] and together with the large number of different cell types and contexts in which it can become activated, it would be surprising if NF-κB subunits always performed the same function and regulated the same (or similar) set of genes in the same way under all circumstances. A question of particular significance is whether NF-κB always functions in the oncogene-like manner described above or are there circumstances where its activity is more similar to a tumour suppressor? In support of the latter role, Gapuzan et al. [21] demonstrated that immortalized rela −/− mouse fibroblasts have many characteristics of transformed cells and could form tumours in immunodeficient mice, although these regressed, indicating that other mutations would be required for a more malignant phenotype. These effects were reversed after the reconstitution of these cells with wild-type RelA, indicating a direct tumoursuppressor-like effect of the NF-κB subunit. A tumour-suppressor function for NF-κB in skin cells has also been proposed, where inhibition of NF-κB can stimulate the development of squamous cell carcinomas [22, 23] . In addition, the overexpression of RelA was found to decrease the tumourigenicity of MCF7 cells in nude mice [24] . Consistent with this tumour-suppressor behaviour, several reports also indicate that RelA is not always antiapoptotic and can, under some circumstances, induce or facilitate cell death [24] [25] [26] [27] [28] [29] . Consistent with these reports, and providing a mechanism to explain (at least in part) their results, we recently found that, when activated by certain inducers or when particular tumour-suppressor proteins are active, RelA represses rather than activates antiapoptotic gene expression [30, 31] .
Regulation of RelA function by ARF (ADP-ribosylation factor)
DNA damage, oncogene activation and cellular stress, which are well-established activators of the p53 tumour suppressor, also regulate NF-κB [19] . Activation of p53 can result in either cell-cycle arrest or induction of apoptosis, whereas, as discussed above, induction of NF-κB is more generally associated with resistance to apoptosis; this suggested that mechanisms must exist within the cell to integrate the activities of these divergent pathways. Consistent with this hypothesis, we and others have reported that p53 and RelA could mutually inhibit the transcriptional activity of each other, establishing a functional relationship between these pathways [32] [33] [34] . In further experiments, we also found that p53 could also regulate the activity of the p52 subunit of NF-κB [35] . Interestingly, and consistent with our overall model, it has also been reported that RelA can facilitate p53-induced cell death [25] .
More recently, we have investigated ARF tumour-suppressor function. ARF is best known for inducing p53 in response to oncogene activation by binding and inhibiting Mdm2 [36] . Many oncogenes, such as Ras and Bcr-Abl, are known to induce NF-κB activity and, in some cases, these have been shown to require NF-κB for cellular transformation [37] [38] [39] [40] . We reasoned, therefore, that since ARF is the first line of defence against oncogene transformation, it would make sense if it also inhibited NF-κB activity in some way, since this, in parallel with its induction of p53, would help promote the suppression of tumourigenesis. Consistent with this hypothesis, we found that ARF could induce the association of RelA with HDAC1 (histone deacetylase 1), thereby turning it into a repressor of gene expression without inducing, inhibiting or affecting NF-κB DNAbinding activity [30] . These effects were independent of p53 and Mdm2. The effects of ARF on RelA were dependent on a threonine residue in the 'activation' domain of RelA, Thr-505, a residue not previously implicated as a site of post-translational modification in RelA. Furthermore, in the absence of ARF, the Bcr-Abl oncogene stimulated NF-κB activity (as reported previously), whereas, in its presence, a repression of transcription was seen. We also found that ARF-modulated NF-κB repressed the transcription of Bcl-X L , an antiapoptotic gene. This did not result in apoptosis, but rather increased the sensitivity to apoptosis induced by other stimuli, such as TNF or etoposide [30] (S. Rocha and N. Perkins, unpublished work). Our results suggest that ARF does more than merely neutralize the antiapoptotic (or oncogenic) activity of RelA. Rather, by inducing its association with HDACs, leading to repression of Bcl-X L , ARF recruits RelA to its tumour-suppressor programme [30, 41] .
Typical and atypical activation of NF-κB
The best-characterized activators of RelA-containing NF-κB complexes are inflammatory cytokines such as TNF and IL-1. However, NF-κB DNA binding is induced by numerous other stimuli, many of which are relevant to tumour initiation or therapy. Such inducers include UV-C (UV light), ionizing radiation, phorbol esters, hypoxia and the chemotherapeutic agents daunorubicin, doxorubicin (adriamycin), etoposide, camptothecin, vincristine, vinblastine and cisplatin [8, 19] . There are clear differences between several inducers of RelA DNA binding, however, which we divide into two broad categories. Typical activators, such as TNF and IL-1 (interleukin-1), induce rapid RelA-complex nuclear localization and DNA binding within minutes after the stimulus is applied [3] . Other inducers of RelA-containing NF-κB complexes, e.g. UV-C and daunorubicin, result in DNA binding with much slower kinetics, reaching a peak after approx. 4 h [31, 42, 43] . We refer to these as atypical activators.
Typical inducers of NF-κB culminate in the activation of the IKK signalosome [3] . A more complicated situation is seen with atypical inducers, where both IKK-dependent and -independent mechanisms of activation have been proposed. Both UV-C and doxorubicin can activate NF-κB in an IKK-independent manner [42, 43] . In contrast, other reports indicate that UV-C-, camptothecin-, doxorubicin-and etoposide-stimulated NF-κB DNA binding is IKK-dependent [44, 45] but with, at least in some cases, a requirement for the zinc finger domain of the IKKγ subunit not seen with TNF [44] . Furthermore, after genotoxic stress, IKKγ becomes sumoylated, whereupon it translocates to the nucleus, becoming ubiquitinated in a step dependent on the ATM checkpoint kinase before being exported back to the cytoplasm, where it mediates the induction of NF-κB [46] .
Repression of transcription by RelA in response to atypical inducers
Although the relative importance of IKK-dependent and -independent mechanisms of NF-κB induction is yet to be resolved in all cases, it is clear that atypical induction of NF-κB displays numerous mechanistic differences from that seen with typical inducers. Hence, we were interested in determining whether these differences were reflected in different functions for RelA induced under these circumstances and whether these would have any implications for the role of NF-κB during cancer therapy. We focused our investigation on NF-κB-regulated gene expression following induction by UV-C and the closely related chemotherapeutic agents, daunorubicin and doxorubicin. Surprisingly, we found that, in response to these stimuli, RelA repressed rather than activated the antiapoptotic NF-κB target genes, Bcl-X L , X-IAP and A20 [31] . This was observed with transiently transfected reporter plasmids and on analysis of endogenous genes. Importantly, the use of siRNAs and rela null cells demonstrated that RelA was required for repression to occur and that this was a dominant inhibitory effect. We found that UV-C and daunorubicin induced the association of RelA with HDACs and resulted in deacetylation of histones at RelA-targeted promoters. Consistent with these effects, we demonstrated that rela null cells, while being extremely sensitive to TNF-induced apoptosis, are actually more resistant to UV-C-induced cell death [31] .
These results show a remarkable similarity to our studies on ARF described above (although ARF modulates the existing NF-κB without inducing its DNA binding). However, there are key mechanistic differences. ARF-mediated repression is dependent on the RelA Thr-505 residue and the ATR (ataxia-telangiectasia-and Rad3-related) checkpoint kinase, something not seen with the atypical activators [31] . Furthermore, whereas ARF expression results in the inhibition of Bcl-X L expression, no repression of the X-IAP gene was observed, a result seen with both UV-C and daunorubicin ( [31] , and S. Rocha and N.D. Perkins, unpublished work). It should not be concluded that all forms of DNA damage result in a repressor form of RelA. Our own results indicate that etoposide (which, similar to daunorubicin/doxorubicin, is a topoisomerase II inhibitor) results in transcriptional activation by RelA ( [31] , and K.J. Campbell and N.D. Perkins, unpublished work). Furthermore, the literature conclusively demonstrates that ionizing radiation also results in the activator form of NF-κB. It is not, therefore, DNA damage itself that leads to transcriptional repression.
Conclusions
Together with results of other laboratories, our results indicate that, under some circumstances, RelA can function as a tumour suppressor by actively repressing antiapoptotic genes [41] . This could be most relevant to the early stages of tumour development, where the oncogenic activities of RelA will not only be curtailed by the action of ARF but, through repression of antiapoptotic genes, RelA could also aid in the elimination of a potential cancer cell. However, if ARF or other components of the pathway regulating RelA become inactivated, the default antiapoptotic function of RelA can no longer be inhibited and it is free to contribute to the survival of the tumour cell. Moreover, our results suggest that with some cancer treatments, in some tumours, NF-κB might contribute to the effectiveness of the therapy rather than inhibit it, as is usually thought. It can be anticipated that these atypical pathways regulating RelA will also be selected against either as a tumour develops or in response to therapy, thereby contributing to the acquisition of chemoresistance. Therefore the actual function of RelA in a cancer cell could vary, depending on the stage of development of the tumour, its tumour-suppressor status and whether (or what type of) anti-cancer therapy has been used. A better understanding of these processes and an ability to analyse RelA function in tumours could therefore lead to improved cancer diagnosis, choice of therapy and, ultimately, development of new anti-cancer drugs.
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